@article{LehriederZapantisPhametal.2023,
  author    = {Lehrieder, Dominik and Zapantis, Nikolaos and Pham, Mirko and Schuhmann, Michael Klaus and Haarmann, Axel},
  title     = {Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report},
  series = {Frontiers in Neurology},
  volume    = {14},
  journal   = {Frontiers in Neurology},
  doi       = {10.3389/fneur.2023.1297341},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-354031},
  year      = {2023},
  abstract  = {Background Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively. Case presentation We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab. Conclusion Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.},
  language  = {en}
}